Poly(anhydride) nanoparticles act as active Th1 adjuvants through toll-like receptor exploitation

Clinical and Vaccine Immunology

Volumn 17, Issue 9, 2010, Pages 1356-1362

  Tamayo, I ^a   Irache, J M ^a   Mansilla, C ^b   Ochoa Reparaz J ^a   Lasarte, J J ^b   Gamazo, C ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; NANOPARTICLE; POLYANHYDRIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; DRUG UPTAKE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SALMONELLA ENTERITIDIS; SALMONELLOSIS; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD86; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENE EXPRESSION; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-12; MALEATES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYETHYLENES; SALMONELLA ENTERITIDIS; SURVIVAL ANALYSIS; TH1 CELLS; TOLL-LIKE RECEPTORS;

EID: 77956408135     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00164-10     Document Type: Article

References (61)

1. Agüeros, M., P. Areses, M. A. Campanero, H. Salman, G. Quincoces, I. Penuelas, and J. M. Irache. 2009. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur. J. Pharm. Sci. 37:231-240.
2. Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85:85-95.
3. Arbós, P., M. Wirth, M. A. Arangoa, F. Gabor, and J. M. Irache. 2002. Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J. Control Release 83:321-330.
4. Baums, C. G., C. Kock, A. Beineke, K. Bennecke, R. Goethe, C. Schroder, K. H. Waldmann, and P. Valentin-Weigand. 2009. Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. Clin. Vaccine Immunol. 16:200-208.
5. Bertholet, S., Y. Goto, L. Carter, A. Bhatia, R. F. Howard, D. Carter, R. N. Coler, T. S. Vedvick, and S. G. Reed. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27:7036-7045.
6. Beutler, B. 2003. Not "molecular patterns" but molecules. Immunity 19:155-156.
7. Bungener, L., F. Geeraedts, V. W. Ter, J. Medema, J. Wilschut, and A. Huckriede. 2008. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26:2350-2359.
8. Champion, C. I., V. A. Kickhoefer, G. Liu, R. J. Moniz, A. S. Freed, L. L. Bergmann, D. Vaccari, S. Raval-Fernandes, A. M. Chan, L. H. Rome, and K. A. Kelly. 2009. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One 4:e5409.
9. Chopra, A., T. S. Kim, I. Sullivan, D. Martinez, and E. P. Cohen. 2006. Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma - a new vaccination strategy. Int. J. Cancer 119:339-348.
10. Da Costa Martins, R., J. M. Irache, J. M. Blasco, M. P. Munoz, C. M. Marin, M. Jesus Grillo, M. Jesus De Miguel, M. Barberan, and C. Gamazo. 2010. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine 28:3038-3046.
11. Da Silva, C. A., D. Hartl, W. Liu, C. G. Lee, and J. A. Elias. 2008. TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J. Immunol. 181:4279-4286.
12. Del Giudice, G. 2003. Vaccination strategies. An overview. Vaccine 21(Suppl. 2):S83-S88.
13. Estevan, M., J. M. Irache, M. J. Grillo, J. M. Blasco, and C. Gamazo. 2006. Encapsulation of antigenic extracts of Salmonella enterica serovar Abortusovis into polymeric systems and efficacy as vaccines in mice. Vet. Microbiol. 118:124-132.
14. Flo, T. H., L. Ryan, E. Latz, O. Takeuchi, B. G. Monks, E. Lien, O. Halaas, S. Akira, G. Skjak-Braek, D. T. Golenbock, and T. Espevik. 2002. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J. Biol. Chem. 277:35489-35495.
15. Galindo-Rodriguez, S. A., E. Allemann, H. Fessi, and E. Doelker. 2005. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22:419-464.
16. Gómez, S., C. Gamazo, B. S. Roman, M. Ferrer, M. L. Sanz, and J. M. Irache. 2007. Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine 25:5263-5271.
17. Gómez, S., C. Gamazo, R. B. San, C. Vauthier, M. Ferrer, and J. M. Irachel. 2006. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J. Nanosci. Nanotechnol. 6:3283-3289.
18. Green, S. J. 2008. Clinical development of TLR agonists as adjuvants: "postalum adjuvant" candidates may reach beyond their intended purpose. Clin. Pharmacol. Ther. 83:813-814.
19. Guy, B. 2007. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5:505-517.
20. Hirata, N., Y. Yanagawa, T. Ebihara, T. Seya, S. Uematsu, S. Akira, F. Hayashi, K. Iwabuchi, and K. Onoe. 2008. Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells. Mol. Immunol. 45:2734-2742.
21. Irache, J. M., H. H. Salman, S. Gomez, S. Espuelas, and C. Gamazo. 2009. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination. Front. Biosci. 2:876-890.
22. Jasani, B., H. Navabi, and M. Adams. 2009. Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27:3401-3404.
23. Jenkins, S. J., J. P. Hewitson, S. Ferret-Bernard, and A. P. Mountford. 2005. Schistosome larvae stimulate macrophage cytokine production through TLR4-dependent and -independent pathways. Int. Immunol. 17:1409-1418.
24. Kanzler, H., F. J. Barrat, E. M. Hessel, and R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13:552-559.
25. Lambert, G., E. Fattal, H. Pinto-Alphandary, A. Gulik, and P. Couvreur. 2000. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17:707-714.
26. Lasarte, J. J., N. Casares, M. Gorraiz, S. Hervas-Stubbs, L. Arribillaga, C. Mansilla, M. Durantez, D. Llopiz, P. Sarobe, F. Borras-Cuesta, J. Prieto, and C. Leclerc. 2007. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J. Immunol. 178:748-756.
27. Lee, J. Y., A. Plakidas, W. H. Lee, A. Heikkinen, P. Chanmugam, G. Bray, and D. H. Hwang. 2003. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J. Lipid Res. 44:479-486.
28. Lindblad, E. B. 2004. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82:497-505.
29. Mann, J. F., R. Acevedo, J. D. Campo, O. Perez, and V. A. Ferro. 2009. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines 8:103-112.
30. Meng, G., A. Grabiec, M. Vallon, B. Ebe, S. Hampel, W. Bessler, H. Wagner, and C. J. Kirschning. 2003. Cellular recognition of tri-/di- palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2. J. Biol. Chem. 278: 39822-39829.
31. Miyake, K. 2007. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 19:3-10. doi:10.1016/ j.smim.2006.12.002.
32. Mizel, S. B., A. N. Honko, M. A. Moors, P. S. Smith, and A. P. West. 2003. Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J. Immunol. 170:6217-6223.
33. Najar, H. M., and J. P. Dutz. 2007. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Eur. J. Immunol. 37:2242-2256.
34. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769-776.
35. Ochoa, J., J. M. Irache, I. Tamayo, A. Walz, V. G. DelVecchio, and C. Gamazo. 2007. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. Vaccine 25:4410-4419.
36. Ochoa-Repáraz, J., B. Sesma, M. Alvarez, R. M. Jesus, J. M. Irache, and C. Gamazo. 2004. Humoral immune response in hens naturally infected with Salmonella Enteritidis against outer membrane proteins and other surface structural antigens. Vet. Res. 35:291-298.
37. O'Hagan, D. T. 2007. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6:699-710.
38. O'Hagan, D. T., A. Wack, and A. Podda. 2007. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82:740-744.
39. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:S63-S68.
40. Perrie, Y., A. R. Mohammed, D. J. Kirby, S. E. McNeil, and V. W. Bramwell. 2008. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364:272-280.
41. Petrovsky, N., and J. C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82:488-496.
42. Pulendran, B. 2004. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199:227-250.
43. Raghu, R., D. Sharma, R. Ramakrishnan, S. Khanam, G. J. Chintalwar, and K. B. Sainis. 2009. Molecular events in the activation of B cells and macrophages by a non-microbial TLR4 agonist, G1-4A from Tinospora cordifolia. Immunol. Lett. 123:60-71.
44. Reis e Sousa, C. 2004. Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16:21-25. doi:10.1016/j.coi.2003. 11.007.
45. Rifkin, I. R., E. A. Leadbetter, L. Busconi, G. Viglianti, and A. Marshak-Rothstein. 2005. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204:27-42.
46. Rowe, R. C., P. J. Sheskey, and S. C. Owen. 2005. Handbook of pharmaceutical excipients. Pharmaceutical Press and American Pharmacist Association, London, United Kingdom.
47. Salman, H. H., C. Gamazo, M. A. Campanero, and J. M. Irache. 2005. Salmonella-like bioadhesive nanoparticles. J. Control Release 106:1-13.
48. Salman, H. H., C. Gamazo, M. A. Campanero, and J. M. Irache. 2006. Bioadhesive mannosylated nanoparticles for oral drug delivery. J. Nanosci. Nanotechnol. 6:3203-3209.
49. Salman, H. H., J. M. Irache, and C. Gamazo. 2009. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 27:4784-4790. doi:10.1016/j.vaccine.2009.05.091.
50. Sharp, F. A., D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, M. Singh, D. T. O'hagan, V. Petrilli, J. Tschopp, L. A. O'Neill, and E. C. Lavelle. 2009. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 106:870-875.
51. Szymczakiewicz-Multanowska, A., N. Groth, R. Bugarini, M. Lattanzi, D. Casula, A. Hilbert, T. Tsai, and A. Podda. 2009. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200:841-848.
52. Tapping, R. I. 2009. Innate immune sensing and activation of cell surface Toll-like receptors. Semin. Immunol. 21:175-184. doi:10.1016/j.smim.2009. 05.003.
53. Tite, J. P., G. Dougan, and S. N. Chatfield. 1991. The involvement of tumor necrosis factor in immunity to Salmonella infection. J. Immunol. 147:3161-3164.
54. Toyota-Hanatani, Y., M. Inoue, T. Ekawa, H. Ohta, S. Igimi, and E. Baba. 2008. Importance of the major Fli C antigenic site of Salmonella enteritidis as a subunit vaccine antigen. Vaccine 26:4135-4137.
55. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146. doi:10.1038/nri1001.
56. Trinchieri, G., and A. Sher. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7:179-190.
57. Valensi, J. P., J. R. Carlson, and G. A. Van Nest. 1994. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153:4029-4039.
58. Wetzler, L. M. 2003. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 21(Suppl. 2):S55-S60.
59. Wischke, C., J. Zimmermann, B. Wessinger, A. Schendler, H. H. Borchert, J. H. Peters, T. Nesselhut, and D. R. Lorenzen. 2009. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm. 365:61-68.
60. Xu, R., and Z. H. Jiang. 2008. Synthesis of beta-(1→4)-oligo-D- mannuronic acid neoglycolipids. Carbohydr. Res. 343:7-17.
61. Yadav, M., and J. S. Schorey. 2006. The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 108:3168-3175.